scholarly journals Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associé à la Grossesse) network

The Breast ◽  
2022 ◽  
Author(s):  
Anne Puchar ◽  
Marie Despierres ◽  
Anne-Sophie Boudy ◽  
Lise Selleret ◽  
Joseph Gligorov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Triple Negative Breast Cancer ◽  
Triple Negative

Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis

2020 ◽  
Vol 39 (1) ◽  
pp. 29-35
Author(s):  
Gabriel De-la-Cruz-Ku ◽  
Bryan Valcarcel ◽  
Zaida Morante ◽  
Mecker G. Möller ◽  
Sofia Lizandro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Propensity Score Analysis ◽  
Breast Conserving Surgery ◽  
Total Mastectomy ◽  
Early Stages ◽  
Score Analysis

scholarly journals Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Heyan Chen ◽  
Lutong Yan ◽  
Shengyu Pu ◽  
Lizhe Zhu ◽  
Huimin Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Reference Value ◽  
Breast Conserving Surgery ◽  
Survival Outcomes ◽  
Seer Database ◽  
Term Survival

Introduction. Knowledge of the effect of prior cancer on long-term survival outcomes for patients with nonmetastatic triple-negative breast cancer (TNBC) remained unclear. The aim of this study was to explore and identify the effectiveness of prior cancer on breast cancer-specific death (BCSD) and other cause-specific death (OCSD) in patients with nonmetastatic TNBC. Materials and Methods. Data of 29,594 participants with nonmetastatic TNBC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2016. Prognostic predictors were identified by propensity score matching (PSM) analysis combined with univariate cumulative incidence function (CIF) and multivariate Fine and Gray competitive risk analyses. Results. Among the women with nonmetastatic TNBC included in the unmatched cohort, a total of 5,375 (18.2%) subjects had prior cancers (P-TNBC) and 24,219 (81.8%) had no prior cancer (NP-TNBC). Patients with P-TNBC tended to have poorer BCSD (Gray’s test, p = 0.0131 ) and OCSD (Gray’s test, p = 0.0009 ) in comparison with those with NP-TNBC after PSM. However, the risk of BCSD p = 0.291 and OCSD p = 0.084 found no difference among P-TNBC patients with one prior cancer and two or more prior cancers after PSM. Additionally, subjects with younger age, advanced T stage, advanced N stage, and advanced differentiation grade tumors were likely to develop BCSD, whereas those with breast-conserving surgery (BCS), radiotherapy, or chemotherapy tended to have a lower incidence of BCSD. Conclusion. Our study demonstrated that prior cancer was related to the worse BCSD and OCSD rate and could be identified as a reliable survival predictor for patients with nonmetastatic TNBC. This study may provide some reference value for the treatment mode of TNBC patients with prior cancer in the future.

scholarly journals Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study

2019 ◽  
Vol 30 ◽  
pp. v64-v65
Author(s):  
M.V. Dieci ◽  
C.A. Giorgi ◽  
G. Griguolo ◽  
S. Angelini ◽  
F. Miglietta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Propensity Score ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Matched Study

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

Immediate and long-term results of the first line chemotherapy in patients with metastatic triple negative breast cancer. Final analysis of randomized study

2020 ◽  
pp. 75-80
Author(s):  
S.A. Lyalkin ◽  
◽  
L.A. Syvak ◽  
N.O. Verevkina ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Randomized Study ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

The objective: was to evaluate the efficacy of the first line chemotherapy in patients with metastatic triple negative breast cancer (TNBC). Materials and methods. Open randomized study was performed including 122 patients with metastatic TNBC. The efficacy and safety of the first line chemotherapy of regimens АТ (n=59) – group 1, patients received doxorubicine 60 мг/м2 and paclitaxel 175 мг/м2 and ТР (n=63) – group 2, patients received paclitaxel 175 мг/м2 and carboplatin AUC 5 were evaluated. Results. The median duration of response was 9.5 months (4.5–13.25 months) in patients received AT regimen and 8.5 months (4.7–12.25 months), in TP regimen; no statistically significant differences were observed, р=0.836. The median progression free survival was 7 months (95% CI 5–26 months) in group 1 and 7.5 months (95% CI 6–35 months) in group 2, p=0.85. Both chemotherapy regimens (AT and TP) had mild or moderate toxicity profiles (grade 1 or 2 in most patients). No significant difference in gastrointestinal toxicity was observed. The incidence of grade 3–4 neutropenia was higher in patients of group 2 (TP regimen): 42.8% versus 27% (р<0.05). Conclusions. Both regimens of chemotherapy (AT and TP) are appropriate to use in the first line setting in patients with metastatic TNBC. Key words: metastatic triple negative breast cancer, chemotherapy, progression free survival, chemotherapy toxicity.

Sign in / Sign up

Export Citation Format

Share Document